Article Text

Download PDFPDF
A pilot study testing a medication algorithm to reduce polypharmacy
  1. L A Mistler1,2,
  2. T A Mellman3,
  3. R E Drake1,4
  1. 1
    Department of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire, USA
  2. 2
    VA National Quality Scholars Fellowship Program, VA Medical Center, White River Junction, Vermont, USA
  3. 3
    Department of Psychiatry, Howard University, Washington, DC, USA
  4. 4
    Departments of Community & Family Medicine and of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire, USA
  1. Dr L A Mistler, VA Quality Scholars Program (11Q), VA Medical Center, White River Junction, VT 05009, USA; lisa.a.mistler{at}


Background: Polypharmacy is common in the treatment of persons with severe mental illness, yet it is not an evidence-based practice. To address this, an attempt was made to reduce medications for patients already receiving polypharmacy during an episode of acute psychiatric hospitalization.

Methods: A medication-reduction algorithm was developed , based on the best available evidence regarding indications for and efficacy of medications and principles of collaborative care. A feasibility pilot study was conducted using a matched case-control design for 12 patients treated with the algorithm and 12 patients treated as usual.

Results: The intervention patients were discharged on significantly fewer medications than controls; symptom reduction and length of stay did not differ significantly.

Conclusion: A collaborative approach to reducing polypharmacy may reverse the trend to add medications during hospitalization.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: The Dartmouth Medical School Quality Research Grant Program provided LAM with support to present this project as a poster at the Fifth Annual Summer Institute on Evidence Based Practices in San Antonio, TX, 29 June to 1 July 2006.

  • Competing interests: None for the first and third authors; speakers’ bureau for Takeda Pharmaceuticals Limited for the second author.

  • Ethics approval: Ethics approval was obtained from The Dartmouth Medical School and New Hampshire State Committees for the Protection of Human Subjects.

  • Patient consent: Obtained.